Treatment with the experimental cancer vaccine OSE2101, given in combination with standard chemotherapy, led to positive early results in…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
A European Medicines Agency (EMA) committee recommended that Jaypirca (pirtobrutinib) be approved to treat some adult patients with chronic lymphocytic…
PANCREATIC CANCER
Immunotherapy shows promise as treatment for pancreatic cancer
Treatment with CAN-2409, an immune-modulating anticancer therapy, showed promising trends toward improved survival in a Phase 2 clinical trial involving…
The presence of more than one high-risk genetic abnormality is associated with dramatically more aggressive multiple myeloma, a study…
Aptose Biosciences will be testing a higher dose of tuspetinib as part of a triple-combination regimen that’s being…
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Regeneron Pharmaceuticals seeking the…
A triple-combination therapy using tuspetinib, Aptose Biosciences‘ experimental oral therapy, is showing potential in treating adults with newly…
PANCREATIC CANCER
PAC-MANN blood test shows high accuracy in ID’ing pancreatic cancer
A new blood test called PAC-MANN can detect the most common type of pancreatic cancer with high accuracy, according…
An experimental immune-modulating therapy called KROS 101 was able to activate immune cells to kill glioma cells in laboratory…
GYNECOLOGICAL CANCER
FDA gives RMAT status to Vigil immunotherapy for ovarian cancer
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Gradalis’ experimental…